Table 3.
Epidemiology data of malignant melanoma.
| No. | Patients before/after COVID-19 | Patient Ratio * | Screening/ Treatment Delay |
DFS |
|---|---|---|---|---|
| 1 [16] | NR | −3.0% | DFU (−30.2%) SFU (−37.0%) SLNB (−29.0%) SE (+31.7%) |
NR |
| 2 [17] | 47 average vs. 32 (2020) | −32.0% | DFU (−20.0%) | NR |
| 3 [18] | 1294 vs. 1465 | +13.0% | DFU (−31.0%) | NR |
| 4 [19] | 278 vs. 284 | +2.22% | NR | NR |
| 5 [20] | 352 vs. 207 | −58.8% | Excision (−41.0%) | NR |
| 6 [21] | 77 vs. 53 | −18.5% | NR | 94% vs. 89% |
| 7 [22] | 634 vs. 556 | −12.3% | NR | NR |
| 8 [23] | 27 vs. 16 | −40.7% | NR | −7% |
| 9 [24] | 40 (18.2%) vs. 10 (23.2%) | +5.0% melanoma −75.0% cases |
NR | NR |
| 10 [25] | NR | NR | TD (−29.0%) | NR |
| 11 [26] | −31.3% | −24.4% | Biopsy (−36.5%) WLE (−22.9%) SLNB (+6.4%) |
NR |
| 12 [27] | 295 average vs. 237 (2020) | −20.0% | NR | NR |
| 13 [28] | 375 vs. 313 | −17.0% | Excision (−11.7%) | NR |
| 14 [29] | NR | −48.0% | DFU (−23.0%) | NR |
| 15 [30] | NR | NR | Excision (−27.0%) | NR |
| 16 [31] | 106 (average) vs. 102 | −5.8% | NR | NR |
| 17 [12] | 163 vs. 138 | −15.3% | TD (−10.8%) | 76.7% vs. 65.9% |
| 18 [32] | 31,910 vs. 29822 | −7.0% | Procedures (−17.0%) | NR |
| 19 [33] | NR | NR | DFU (−23.2%) Excision (−28.1%) |
NR |
| 20 [34] | 294 vs. 237 | −19.4% | NR | NR |
| 21 [35] | NR | NR | SLNB (−1.7%) DFU (−10.4%) |
87.6% vs. 57.1% |
| 22 [11] | 2468 vs. 2034 | −17.6% | NR | NR |
| 23 [36] | 172 vs. 153 | −11.0% | NR | NR |
| 24 [37] | 466 vs. 432 | −7.3% | NR | NR |
| 25 [38] | 794 vs. 524 | −34.0% | NR | NR |
| 26 [39] | 51 vs. 61 | +19.6% | TD (10 days) | NR |
| 27 [40] | 327 vs. 306 (average) | −6.4% | NR | NR |
| 28 [41] | 193 (average) vs. 196 | +1.6% | NR | NR |
| 29 [42] | 78 vs. 84 | +7.7% | NR | NR |
| 30 [43] | NR | NR | NR | NR |
| 31 [44] | 192 vs. 181 | −15.4% | NR | 94.0% vs. 94.0% |
| 32 [45] | 224 vs. 237 | +5.8% | SFU (+2.3 months) | NR |
| 33 [46] | 2062 vs. 1834 | −11.1% | NR | NR |
| 34 [47] | 20 vs. 16 | −20.0% | NR | NR |
| 35 [9] | 22 vs. 25 | +12.0% | NR | NR |
| 36 [48] | 320 vs. 319 vs. 347 | NR | SLNB (+9.5%) | NR |
| 37 [49] | 246 vs. 246 | NR | TD (34.5 days) | NR |
| 38 [50] | 53 (average) vs. 25 | −52.8% | NR | NR |
| 39 [51] | 191 vs. 105 | −45.0% | NR | NR |
* Patient ratio— patients before pandemic/patients during pandemic; NR—not reported; DFU—Dermatologic follow-up; SFU—Surgical follow-up; SLNB—Sentinel lymph-node biopsy; LND—Lymph node dissection; DFS—Disease-free survival; TD—Treatment delay; WLE—Wide local excision.